TG Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
March 04 2021 - 07:30AM
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael
S. Weiss, the Company’s Executive Chairman and Chief Executive
Officer, will present at the H.C. Wainwright Global Life Sciences
Conference, being held virtually March 9 – 10, 2021. The
presentation will be accessible for on-demand download beginning on
Tuesday, March 9, 2021 at 7:00 AM ET.
A replay of this presentation will be available on the Events
page, located within the Investors & Media section, of the
Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS, INC.TG
Therapeutics is a fully-integrated, commercial stage
biopharmaceutical company focused on the acquisition, development
and commercialization of novel treatments for B-cell malignancies
and autoimmune diseases. In addition to an active research pipeline
including five investigational medicines across these therapeutic
areas, TG has received accelerated approval from
the U.S. FDA for UKONIQ™ (umbralisib), for the
treatment of adult patients with relapsed/refractory marginal zone
lymphoma who have received at least one prior anti-CD20-based
regimen and relapsed/refractory follicular lymphoma who have
received at least three prior lines of systemic therapies.
Currently, the Company has two programs in Phase 3 development for
the treatment of patients with relapsing forms of multiple
sclerosis (RMS) and patients with chronic lymphocytic leukemia
(CLL) and several investigational medicines in Phase 1 clinical
development. For more
information, visit www.tgtherapeutics.com, and follow us
on Twitter @TGTherapeutics and Linkedin.
UKONIQ™ is a trademark of TG Therapeutics, Inc.
CONTACT: |
|
Investor Relations |
|
Email: ir@tgtxinc.com |
|
Telephone: 1.877.575.TGTX (8489), Option 4 |
|
|
|
Media Relations: |
|
Email: media@tgtxinc.com |
|
Telephone: 1.877.575.TGTX (8489), Option 6 |
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Mar 2023 to Mar 2024